Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 24.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of MeiraGTx Holdings was 27.70% per year. The lowest was -17.50% per year. And the median was 10.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
MeiraGTx Holdings 5-Year EBITDA Growth Rate Related Terms
FRA:328 vs JBIO, VOR, OMER: 5-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings 5-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 5.40% mean?
MeiraGTx Holdings (FRA:328) has a 5-Year EBITDA Growth Rate of 5.40% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for MeiraGTx Holdings and its competitors.
Is MeiraGTx Holdings' 5-Year EBITDA Growth Rate too high?
MeiraGTx Holdings' current 5-Year EBITDA Growth Rate is 5.40%. Overall, MeiraGTx Holdings has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' 5-Year EBITDA Growth Rate compare to JBIO and VOR?
MeiraGTx Holdings' 5-Year EBITDA Growth Rate of 5.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current 5-Year EBITDA Growth Rate is 5.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €86.94, compared to a current price of €11.90 — trading 86.3% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 5.40%. MeiraGTx Holdings' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current 5-Year EBITDA Growth Rate is 5.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €11.90 is trading 86.3% below its estimated GF Value™ of €86.94.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for FRA:328:
5-Year EBITDA Growth Rate: 5.40%
GF Value™: €86.94 vs. price of €11.90 (86.3% below fair value)
No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
60GF Score
Get the complete analysis for FRA:328
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:328 has been successfully added to your 
